<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HE36D956E38D84C0AB677E8B8DDED7FAF" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 27 IH: Halt All Lethal Trafficking of Fentanyl Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-01-03</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 27</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250103">January 3, 2025</action-date><action-desc><sponsor name-id="G000568">Mr. Griffith</sponsor> (for himself, <cosponsor name-id="L000566">Mr. Latta</cosponsor>, <cosponsor name-id="G000558">Mr. Guthrie</cosponsor>, <cosponsor name-id="B001257">Mr. Bilirakis</cosponsor>, <cosponsor name-id="H001067">Mr. Hudson</cosponsor>, <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>, <cosponsor name-id="P000609">Mr. Palmer</cosponsor>, <cosponsor name-id="D000628">Mr. Dunn of Florida</cosponsor>, <cosponsor name-id="C001120">Mr. Crenshaw</cosponsor>, <cosponsor name-id="J000302">Mr. Joyce of Pennsylvania</cosponsor>, <cosponsor name-id="P000048">Mr. Pfluger</cosponsor>, <cosponsor name-id="H001086">Mrs. Harshbarger</cosponsor>, <cosponsor name-id="C001039">Mrs. Cammack</cosponsor>, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, <cosponsor name-id="W000809">Mr. Womack</cosponsor>, <cosponsor name-id="B001260">Mr. Buchanan</cosponsor>, <cosponsor name-id="M001205">Mrs. Miller of West Virginia</cosponsor>, <cosponsor name-id="M001194">Mr. Moolenaar</cosponsor>, <cosponsor name-id="B001295">Mr. Bost</cosponsor>, <cosponsor name-id="E000300">Mr. Evans of Colorado</cosponsor>, <cosponsor name-id="F000471">Mr. Fitzgerald</cosponsor>, <cosponsor name-id="L000600">Mr. Langworthy</cosponsor>, <cosponsor name-id="C001118">Mr. Cline</cosponsor>, <cosponsor name-id="M001204">Mr. Meuser</cosponsor>, <cosponsor name-id="V000133">Mr. Van Drew</cosponsor>, <cosponsor name-id="F000446">Mr. Feenstra</cosponsor>, and <cosponsor name-id="N000193">Mr. Nunn of Iowa</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Controlled Substances Act with respect to the scheduling of fentanyl-related substances, and for other purposes.</official-title></form><legis-body id="HCDADFC0EB27341C99B70A681B043D3D1" style="OLC"><section id="H2FCC7848A46F49629E0893865EB0E687" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Halt All Lethal Trafficking of Fentanyl Act</short-title></quote> or the <quote><short-title>HALT Fentanyl Act</short-title></quote>.</text></section><section id="HF4AADB678F194A1984012ECD5EDB9C7E"><enum>2.</enum><header>Class scheduling of fentanyl-related substances</header><text display-inline="no-display-inline">Section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>) is amended by adding at the end of schedule I the following:</text><quoted-block id="H59628388CA244061936C0C27763B9A07" style="OLC"><subsection id="H090E640C425C4D9FB13E9F6FFCEA265E"><enum>(e)</enum><paragraph commented="no" display-inline="yes-display-inline" id="H5CACE78442C54CF68B0E1D6FCA88D717"><enum>(1)</enum><text>Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a fentanyl-related substance, or which contains the salts, isomers, and salts of isomers of a fentanyl-related substance whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.</text></paragraph><paragraph id="H322D0D86322648A2900BDFFFC3BA128D"><enum>(2)</enum><text>For purposes of paragraph (1), except as provided in paragraph (3), the term <quote>fentanyl-related substance</quote> means any substance that is structurally related to fentanyl by 1 or more of the following modifications:</text><subparagraph id="H66C59DE8C9994A18B1E8F2ABC90F7B9F"><enum>(A)</enum><text>By replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle.</text></subparagraph><subparagraph id="H79D274E446804F42B933534F5D888F4E"><enum>(B)</enum><text>By substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups.</text></subparagraph><subparagraph id="HEA22C3642B0040CEBAF151C16CF66195"><enum>(C)</enum><text>By substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups.</text></subparagraph><subparagraph id="HB4CEE999B76549D98778A823F72B1706"><enum>(D)</enum><text>By replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle.</text></subparagraph><subparagraph id="HCD2D33B15D884D21BE3496D96D841B28"><enum>(E)</enum><text>By replacement of the N–propionyl group with another acyl group.</text></subparagraph></paragraph><paragraph id="HB1B6CAB841524D0282A96B9D41013447"><enum>(3)</enum><text>A substance that satisfies the definition of the term <quote>fentanyl-related substance</quote> in paragraph (2) shall nonetheless not be treated as a fentanyl-related substance subject to this schedule if the substance—</text><subparagraph id="HBC742C69A3C74E68AFDF8C63820E92D1"><enum>(A)</enum><text>is controlled by action of the Attorney General under section 201; or</text></subparagraph><subparagraph id="H8B7A208D7B2F4FB5AB9B157EC6F41C95"><enum>(B)</enum><text>is otherwise expressly listed in a schedule other than this schedule.</text></subparagraph></paragraph><paragraph id="H3DC84451CA334342814319AB06FEC062"><enum>(4)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H17EBAB9524984802B27F58068CA2D213"><enum>(A)</enum><text>The Attorney General may by order publish in the Federal Register a list of substances that satisfy the definition of the term <quote>fentanyl-related substance</quote> in paragraph (2).</text></subparagraph><subparagraph id="H789E4C5E32334A139144D9606590A081"><enum>(B)</enum><text>The absence of a substance from a list published under subparagraph (A) does not negate the control status of the substance under this schedule if the substance satisfies the definition of the term <quote>fentanyl-related substance</quote> in paragraph (2).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="HA37A13E5198443A39D4A4A3079EA82D5"><enum>3.</enum><header>Registration requirements related to research</header><subsection id="HFF96CBA792D0400AB8047813CCA09302"><enum>(a)</enum><header>Alternative registration process for schedule I research</header><text>Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended—</text><paragraph id="HD2111586E5EB414D9A95F1062EA4C102"><enum>(1)</enum><text>by redesignating the second subsection (l) (relating to required training for prescribers) as subsection (m); and</text></paragraph><paragraph id="HF0239FCCCC504D668774CDC0808DC2B9"><enum>(2)</enum><text>by adding at the end the following:</text><quoted-block id="H42479F3AD78A4D6F87B2EDC0E9E15D59" style="OLC"><subsection id="HE845D4BC28DB486FA255135BFACC8BFE"><enum>(n)</enum><header>Special provisions for practitioners conducting certain research with schedule i controlled substances</header><paragraph id="HE47837B436C54B1AB72EDEA396EFB87D"><enum>(1)</enum><header>In general</header><text>Notwithstanding subsection (g), a practitioner may conduct research described in paragraph (2) of this subsection with 1 or more schedule I substances in accordance with subparagraph (A) or (B) of paragraph (3) of this subsection.</text></paragraph><paragraph id="HBAA0BD32FCEB4BEEB3CA147CBC92C669"><enum>(2)</enum><header>Research subject to expedited procedures</header><text>Research described in this paragraph is research that—</text><subparagraph id="HBF80A5C401694F159B47EBAD8F854D9F"><enum>(A)</enum><text>is with respect to a drug that is the subject of an investigational use exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act; or</text></subparagraph><subparagraph id="HA51750A6B6F94D4F9B8313E31E58DEDC"><enum>(B)</enum><text>is—</text><clause id="HA73999475CB44163A8E7AADB3EFB64F5"><enum>(i)</enum><text>conducted by the Department of Health and Human Services, the Department of Defense, or the Department of Veterans Affairs; or</text></clause><clause id="HB02B45F16F1D4EF99749D32495BCABDD"><enum>(ii)</enum><text>funded partly or entirely by a grant, contract, cooperative agreement, or other transaction from the Department of Health and Human Services, the Department of Defense, or the Department of Veterans Affairs.</text></clause></subparagraph></paragraph><paragraph id="H9513519465F242E4AF4C6571E1BCFF3A"><enum>(3)</enum><header>Expedited procedures</header><subparagraph id="HCABE3D55AD7C4EA4AE8DE38879D72689"><enum>(A)</enum><header>Researcher with a current schedule i or ii research registration</header><clause id="H9DC033CA601140AFA08CCED3584E2BA7"><enum>(i)</enum><header>In general</header><text>If a practitioner is registered to conduct research with a controlled substance in schedule I or II, the practitioner may conduct research under this subsection on and after the date that is 30 days after the date on which the practitioner sends a notice to the Attorney General containing the following information, with respect to each substance with which the practitioner will conduct the research:</text><subclause id="HE20C0054640B4181928BB68AAA67DB79"><enum>(I)</enum><text>The chemical name of the substance.</text></subclause><subclause id="H7AFD41ECE5A5498BA1C917FF72893150"><enum>(II)</enum><text>The quantity of the substance to be used in the research.</text></subclause><subclause id="H0D32A5DD34F0442584F857283BBE943A"><enum>(III)</enum><text>Demonstration that the research is in the category described in paragraph (2), which demonstration may be satisfied—</text><item id="HCDE949B7CCC64C76B8026B4685756B0D"><enum>(aa)</enum><text>in the case of a grant, contract, cooperative agreement, or other transaction, or intramural research project, by identifying the sponsoring agency and supplying the number of the grant, contract, cooperative agreement, other transaction, or project; or</text></item><item id="HD5018B4410A349FAAAF241BFF5D273C7"><enum>(bb)</enum><text>in the case of an application under section 505(i) of the Federal Food, Drug, and Cosmetic Act, by supplying the application number and the sponsor of record on the application.</text></item></subclause><subclause id="H33E2E91B2A384A0185A92011CAF74055"><enum>(IV)</enum><text>Demonstration that the researcher is authorized to conduct research with respect to the substance under the laws of the State in which the research will take place.</text></subclause></clause><clause id="H9DFC573EEEB44E7EBE80FE9266A91FA6"><enum>(ii)</enum><header>Verification of information by hhs or va</header><text>Upon request from the Attorney General, the Secretary of Health and Human Services, the Department of Defense, or the Secretary of Veterans Affairs, as appropriate, shall verify information submitted by an applicant under clause (i)(III).</text></clause></subparagraph><subparagraph id="H5FBE3BB71B254EB78305E6462F36EEA5"><enum>(B)</enum><header>Researcher without a current schedule i or ii research registration</header><clause id="HCBA34ABD437E4EF8950D22F97F7920A5"><enum>(i)</enum><header>In general</header><text>If a practitioner is not registered to conduct research with a controlled substance in schedule I or II, the practitioner may send a notice to the Attorney General containing the information listed in subparagraph (A)(i), with respect to each substance with which the practitioner will conduct the research.</text></clause><clause id="HF568D0A65C984030BDFBE843C98CF5DA"><enum>(ii)</enum><header>Attorney general action</header><text>The Attorney General shall—</text><subclause id="HBE290DB9C3C64027A78DCEE314205555"><enum>(I)</enum><text>treat notice received under clause (i) as a sufficient application for a research registration; and</text></subclause><subclause id="HD21CDA6795FE46CAB613FC30713CA286"><enum>(II)</enum><text>not later than 45 days of receiving such a notice that contains all information required under subparagraph (A)(i)—</text><item id="H7BA7BF4716EB493ABD54F3FB0890CEEA"><enum>(aa)</enum><text>register the applicant; or</text></item><item id="H78E5774B519E4ACE87B97B5868E90C19"><enum>(bb)</enum><text>serve an order to show cause upon the applicant in accordance with section 304(c).</text></item></subclause></clause></subparagraph></paragraph><paragraph id="HAAC2DBA2AC84452AB5E239C175366741"><enum>(4)</enum><header>Electronic submissions</header><text>The Attorney General shall provide a means to permit a practitioner to submit a notification under paragraph (3) electronically.</text></paragraph><paragraph id="H8DC9BA7382D04FCF85B6ED3941078F09"><enum>(5)</enum><header>Limitation on amounts</header><text>A practitioner conducting research with a schedule I substance under this subsection may only possess the amounts of schedule I substance identified in—</text><subparagraph id="HA8BB64E39DE9429A92DC8776EA2CDEE2"><enum>(A)</enum><text>the notification to the Attorney General under paragraph (3); or</text></subparagraph><subparagraph id="HCFFAD54355D94EB39D85EF1561699C60"><enum>(B)</enum><text>a supplemental notification that the practitioner may send if the practitioner needs additional amounts for the research, which supplemental notification shall include—</text><clause id="HB019B7DE7C434BA4BA2DB5922F65F90F"><enum>(i)</enum><text>the name of the practitioner;</text></clause><clause id="HC0B7947419F34ABDB466FDF0A8B310DA"><enum>(ii)</enum><text>the additional quantity needed of the substance; and</text></clause><clause id="HA59D6F51D92245D2B70D79A5196429CA"><enum>(iii)</enum><text>an attestation that the research to be conducted with the substance is consistent with the scope of the research that was the subject of the notification under paragraph (3).</text></clause></subparagraph></paragraph><paragraph id="H12F06D73CC9A48CB99E14BFDA9B46585"><enum>(6)</enum><header>Importation and exportation requirements not affected</header><text>Nothing in this subsection alters the requirements of part A of title III, regarding the importation and exportation of controlled substances.</text></paragraph><paragraph id="H9F7DD2AC8EF546F4830D329727473BB2"><enum>(7)</enum><header>Inspector general report</header><text>Not later than 1 year after the date of enactment of this Act, the Inspector General of the Department of Justice shall complete a study, and submit a report thereon, about research described in paragraph (2) of this subsection with fentanyl.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HA573A355E09A47E884A8D6F0A914A4C3"><enum>(b)</enum><header>Separate registrations not required for additional researcher in same institution</header><paragraph id="HDF85939979BA4E03829D2769B256B7DF"><enum>(1)</enum><header>In general</header><text>Section 302(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822(c)</external-xref>) is amended by adding at the end the following:</text><quoted-block id="H27E629F783B8450B936D61DDB857B5BC" style="OLC"><paragraph id="H7C7A7CC815B04E4CBD37150FBD25FF39"><enum>(4)</enum><text>An agent or employee of a research institution that is conducting research with a controlled substance if—</text><subparagraph id="HDF194F13C6624FEB8ABF6318BC03EB04"><enum>(A)</enum><text>the agent or employee is acting within the scope of the professional practice of the agent or employee;</text></subparagraph><subparagraph id="HD6213A708E70454B91D34757A3BF4B5E"><enum>(B)</enum><text>another agent or employee of the institution is registered to conduct research with a controlled substance in the same schedule;</text></subparagraph><subparagraph id="HFDF66F02B7724FB8A735E6B30D3B7229"><enum>(C)</enum><text>the researcher who is so registered—</text><clause id="H18BF064FA59547E69CD3B7287ED3B942"><enum>(i)</enum><text>informs the Attorney General of the name, position title, and employing institution of the agent or employee who is not separately registered;</text></clause><clause id="HBCEE050A91D241038932B6D566B40261"><enum>(ii)</enum><text>authorizes that agent or employee to perform research under the registration of the registered researcher; and</text></clause><clause id="H865F6A6E0C3A494683043D3D4318810A"><enum>(iii)</enum><text>affirms that any act taken by that agent or employee involving a controlled substance shall be attributable to the registered researcher, as if the researcher had directly committed the act, for purposes of any proceeding under section 304(a) to suspend or revoke the registration of the registered researcher; and</text></clause></subparagraph><subparagraph id="H2CA24E4E84E74C4CA0AC9274279B3B6E"><enum>(D)</enum><text>the Attorney General does not, within 30 days of receiving the information, authorization, and affirmation described in subparagraph (C), refuse, for a reason listed in section 304(a), to allow the agent or employee to possess the substance without a separate registration.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="HC8F4DE0E4AF241CC8E303E77E5AFD10B"><enum>(2)</enum><header>Technical correction</header><text display-inline="yes-display-inline">Section 302(c)(3) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822(c)(3)</external-xref>) is amended by striking <quote>(25)</quote> and inserting <quote>(27)</quote>. </text></paragraph></subsection><subsection id="H56DA842DF87B4C099CCECE43C68A1915"><enum>(c)</enum><header>Single registration for related research sites</header><text>Section 302(e) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822(e)</external-xref>) is amended by adding at the end the following:</text><quoted-block id="HF040FAE90A3041A9AE66DE9F62E96F7D" style="OLC"><paragraph id="HA720EA36F0324DD1B6F7BBB0F826510E"><enum>(4)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="HFF89B49B582144FBA1169100781BB57C"><enum>(A)</enum><text>Notwithstanding paragraph (1), a person registered to conduct research with a controlled substance under section 303(f) may conduct the research under a single registration if—</text><clause id="H030F95CBE50542BFBBA72C848518C3FE"><enum>(i)</enum><text>the research occurs exclusively on sites all of which are—</text><subclause id="H90D991D66108460CB7763A248091E7AB"><enum>(I)</enum><text>within the same city or county; and</text></subclause><subclause id="H44CC6270DFE14BB8B49C59D2C8E2A10F"><enum>(II)</enum><text>under the control of the same institution, organization, or agency; and</text></subclause></clause><clause id="H2997396BD7DB41E5A3489AEFFB73399E"><enum>(ii)</enum><text>before commencing the research, the researcher notifies the Attorney General of each site where—</text><subclause id="H1B0915013C7749D4992DDB060C8C6646"><enum>(I)</enum><text>the research will be conducted; or</text></subclause><subclause id="HBE25A4EC83C142B28886B06E9BA42186"><enum>(II)</enum><text>the controlled substance will be stored or administered.</text></subclause></clause></subparagraph><subparagraph id="H6A6678DDC9864CC8B34DFC839F531E12"><enum>(B)</enum><text>A site described in subparagraph (A) shall be included in a registration described in that subparagraph only if the researcher has notified the Attorney General of the site—</text><clause id="H90406560145949C3B5A71EFC6BDC3B8B"><enum>(i)</enum><text>in the application for the registration; or</text></clause><clause id="H8C9A9D08759F4F9BAECB92F23A3FE36C"><enum>(ii)</enum><text>before the research is conducted, or before the controlled substance is stored or administered, at the site.</text></clause></subparagraph><subparagraph id="H35BF135DAFE941C2B8F79594085415AF"><enum>(C)</enum><text>The Attorney General may, in consultation with the Secretary, issue regulations addressing, with respect to research sites described in subparagraph (A)—</text><clause id="H1135E678B8324C4EBB32E4CAC5F6E1D4"><enum>(i)</enum><text>the manner in which controlled substances may be delivered to the research sites;</text></clause><clause id="HA07369B580474406940A9F7E51A5325E"><enum>(ii)</enum><text>the storage and security of controlled substances at the research sites;</text></clause><clause id="HF286BAA6EB1C4C91B5EAB344FB638533"><enum>(iii)</enum><text>the maintenance of records for the research sites; and</text></clause><clause id="HB142541A6E3C42D9842DE7EF431E85C3"><enum>(iv)</enum><text>any other matters necessary to ensure effective controls against diversion at the research sites.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H34E475DEDC6A41999D66D8861CA43750"><enum>(d)</enum><header>New inspection not required in certain situations</header><text>Section 302(f) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822(f)</external-xref>) is amended—</text><paragraph id="H9CBEA8425DE64608A7FCD8A96E27C9E9"><enum>(1)</enum><text>by striking <quote>(f) The</quote> and inserting <quote>(f)(1) The</quote>; and</text></paragraph><paragraph id="HC2AB9D81AC4848CA923CC7B7CCE866AD"><enum>(2)</enum><text>by adding at the end the following:</text><quoted-block id="H0C727E3C9BA8482B9058FB235720EF5D" style="OLC"><paragraph id="H70B1F400D991493C8F94232465A7E686"><enum>(2)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="HC7C40931660F4C58AA5D9295318F9CA3"><enum>(A)</enum><text>If a person is registered to conduct research with a controlled substance and applies for a registration, or for a modification of a registration, to conduct research with a second controlled substance that is in the same schedule as the first controlled substance, or is in a schedule with a higher numerical designation than the schedule of the first controlled substance, a new inspection by the Attorney General of the registered location is not required.</text></subparagraph><subparagraph id="HBAF625D2878B4D67A4AED9DD507760DC" indent="up1"><enum>(B)</enum><text>Nothing in subparagraph (A) shall prohibit the Attorney General from conducting an inspection that the Attorney General determines necessary to ensure that a registrant maintains effective controls against diversion.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H88F2DBD4FBA3478FB99DAEE3CD03A55D"><enum>(e)</enum><header>Continuation of research on substances newly added to schedule I</header><text>Section 302 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822</external-xref>) is amended by adding at the end the following:</text><quoted-block id="HF2DD7B8DE1F849C3B98D749B7823812E" style="OLC"><subsection id="HBE3F754449774CADA98518966F7AEC5B"><enum>(h)</enum><header>Continuation of research on substances newly added to schedule I</header><text>If a person is conducting research on a substance when the substance is added to schedule I, and the person is already registered to conduct research with a controlled substance in schedule I—</text><paragraph id="H6D7B4E589F30481593D6DB78837ABA02"><enum>(1)</enum><text>not later than 90 days after the scheduling of the newly scheduled substance, the person shall submit a completed application for registration or modification of existing registration, to conduct research on the substance, in accordance with regulations issued by the Attorney General for purposes of this paragraph;</text></paragraph><paragraph id="H9BE468230F9D4DEFADCDBBF98828D59D"><enum>(2)</enum><text>the person may, notwithstanding subsections (a) and (b), continue to conduct the research on the substance until—</text><subparagraph id="HE0DAFC36617F4536B8388E615BCBA7BB"><enum>(A)</enum><text>the person withdraws the application described in paragraph (1) of this subsection; or</text></subparagraph><subparagraph id="H5858CACCE92546559A49D931D22AA3B2"><enum>(B)</enum><text>the Attorney General serves on the person an order to show cause proposing the denial of the application under section 304(c);</text></subparagraph></paragraph><paragraph id="HB83434541E2344438C6AF863F00E77AB"><enum>(3)</enum><text>if the Attorney General serves an order to show cause as described in paragraph (2)(B) and the person requests a hearing, the hearing shall be held on an expedited basis and not later than 45 days after the request is made, except that the hearing may be held at a later time if so requested by the person; and</text></paragraph><paragraph id="H6205D9CE2920431F84E443CE92B233A1"><enum>(4)</enum><text>if the person sends a copy of the application described in paragraph (1) to a manufacturer or distributor of the substance, receipt of the copy by the manufacturer or distributor shall constitute sufficient evidence that the person is authorized to receive the substance.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H3A644F9A86324D2295BDD50EB21B7A4D"><enum>(f)</enum><header>Treatment of certain manufacturing activities as coincident to research</header><text>Section 302 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/822">21 U.S.C. 822</external-xref>), as amended by subsection (e), is amended by adding at the end the following:</text><quoted-block style="OLC" id="H731846FBE66A4EF7B60B9F9758371784" display-inline="no-display-inline"><subsection id="HBCD132C532BE49909504C742E97D69CC"><enum>(i)</enum><header>Treatment of certain manufacturing activities as coincident to research</header><paragraph id="H3C6864DEF3A647D3B6C149CCE642368B"><enum>(1)</enum><header>In general</header><text>Except as provided in paragraph (3), a person who is registered to perform research on a controlled substance may perform manufacturing activities with small quantities of that substance, including activities described in paragraph (2), without being required to obtain a manufacturing registration, if—</text><subparagraph id="H009AD630264949238293FF759D0B3E77"><enum>(A)</enum><text>the activities are performed for the purpose of the research; and</text></subparagraph><subparagraph id="H05E9F6AF938F43C29A4A0A41BFBA0045"><enum>(B)</enum><text>the activities and the quantities of the substance involved in the activities are stated in—</text><clause id="HCC8D065D16854BAE8139DE6040255891"><enum>(i)</enum><text>a notification submitted to the Attorney General under section 303(l);</text></clause><clause id="HCC54421C275A4DF59174A2A4ADFDFBD6"><enum>(ii)</enum><text>a research protocol filed with an application for registration approval under section 303(f); or</text></clause><clause id="H7DF0BA8CB09E4E71AF37251D213DA98F"><enum>(iii)</enum><text>a notification to the Attorney General that includes—</text><subclause id="H3A99635CF7044732A0EE5261DB7C8576"><enum>(I)</enum><text>the name of the registrant; and</text></subclause><subclause id="H09ED94A9E3C74A7B9098DA8A615ACF44"><enum>(II)</enum><text>an attestation that the research to be conducted with the small quantities of manufactured substance is consistent with the scope of the research that is the basis for the registration.</text></subclause></clause></subparagraph></paragraph><paragraph id="H45694F79E4254C69BF91A0CFEB133243"><enum>(2)</enum><header>Activities included</header><text>Activities permitted under paragraph (1) include—</text><subparagraph id="H881F603F192E42D190B424CF52835B30"><enum>(A)</enum><text>processing the substance to create extracts, tinctures, oils, solutions, derivatives, or other forms of the substance consistent with—</text><clause id="HCD378BDDE02142DD921A713D7D737A94"><enum>(i)</enum><text>the information provided as part of a notification submitted to the Attorney General under section 303(l); or</text></clause><clause id="HE7337BBB90004B7B91D28B5D08BC92B1"><enum>(ii)</enum><text>a research protocol filed with an application for registration approval under section 303(f); and</text></clause></subparagraph><subparagraph id="H26A52BE1812142BD9CDE76C3BC5F7CC9"><enum>(B)</enum><text>dosage form development studies performed for the purpose of requesting an investigational new drug exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>).</text></subparagraph></paragraph><paragraph id="HC4736E545C074D35950A43A01AB2A5B2"><enum>(3)</enum><header>Exception regarding marihuana</header><text>The authority under paragraph (1) to manufacture substances does not include the authority to grow marihuana.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H18797443B40B445B853A74A9F33ABF7E"><enum>(g)</enum><header>Transparency regarding special procedures</header><text>Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>), as amended by subsection (a), is amended by adding at the end the following:</text><quoted-block id="H0152907FBB5C4949AD65D629B58B0ED6" style="OLC"><subsection id="HB3A836AAA03F403DB86669F87E009994"><enum>(o)</enum><header>Transparency regarding special procedures</header><paragraph id="H83687469A3194AC7AFEA967FEC22DED8"><enum>(1)</enum><header>In general</header><text>If the Attorney General determines, with respect to a controlled substance, that an application by a practitioner to conduct research with the substance should be considered under a process, or subject to criteria, different from the process or criteria applicable to applications to conduct research with other controlled substances in the same schedule, the Attorney General shall make public, including by posting on the website of the Drug Enforcement Administration—</text><subparagraph id="H4351D5F5F65D496EBE25EDF58E147743"><enum>(A)</enum><text>the identities of all substances for which such determinations have been made;</text></subparagraph><subparagraph id="H5C9A42B49E084E00A0E04B1D4761C07D"><enum>(B)</enum><text>the process and criteria that shall be applied to applications to conduct research with those substances; and</text></subparagraph><subparagraph id="HBBFC64517E804CF6AC4656617FF481F3"><enum>(C)</enum><text>how the process and criteria described in subparagraph (B) differ from the process and criteria applicable to applications to conduct research with other controlled substances in the same schedule.</text></subparagraph></paragraph><paragraph id="H1CA349845F7E466F8F1CCD54C321E6D3"><enum>(2)</enum><header>Timing of posting</header><text>The Attorney General shall make information described in paragraph (1) public upon making a determination described in that paragraph, regardless of whether a practitioner has submitted such an application at that time.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="HF01187544B8A4712A1238A54AD9C13D9" display-inline="no-display-inline"><enum>4.</enum><header>Technical correction on controlled substances dispensing</header><text display-inline="no-display-inline">Effective as if included in the enactment of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>—</text><paragraph id="H2A303E6B792D46378DF304E2128B167C"><enum>(1)</enum><text>section 1252(a) of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref> (136 Stat. 5681) is amended, in the matter being inserted into section 302(e) of the Controlled Substances Act, by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>;</text></paragraph><paragraph id="H9A37DF320B1C438FA145BA72CAE11CCF"><enum>(2)</enum><text>section 1262 of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref> (136 Stat. 5681) is amended—</text><subparagraph id="H8A1837B5671740A98D9DFC1BABEF40B7"><enum>(A)</enum><text>in subsection (a)—</text><clause id="H7399024D4EBF49058FC7E2048DF4B03A"><enum>(i)</enum><text>in the matter preceding paragraph (1), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>;</text></clause><clause id="HDAC7627F53D7481CBFF708C88E14A5D3"><enum>(ii)</enum><text>in the matter being stricken by subsection (a)(2), by striking <quote>(g)(1)</quote> and inserting <quote>(h)(1)</quote>; and</text></clause><clause id="HB2FA12BBC0A04984A6740FE9C3D0547B"><enum>(iii)</enum><text>in the matter being inserted by subsection (a)(2), by striking <quote>(g) Practitioners</quote> and inserting <quote>(h) Practitioners</quote>; and</text></clause></subparagraph><subparagraph id="H60B797B6311E48B385BC2819663B5EEF"><enum>(B)</enum><text>in subsection (b)—</text><clause id="H9C4D59B8D65E4B479F517E57CA3927EC"><enum>(i)</enum><text>in the matter being stricken by paragraph (1), by striking <quote>303(g)(1)</quote> and inserting <quote>303(h)(1)</quote>;</text></clause><clause id="HC4F85BC24D8C44ECBBD97918FC165B0A"><enum>(ii)</enum><text>in the matter being inserted by paragraph (1), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>;</text></clause><clause id="H54965E6FC7534ED6AABC7E12AD7E03F9"><enum>(iii)</enum><text>in the matter being stricken by paragraph (2)(A), by striking <quote>303(g)(2)</quote> and inserting <quote>303(h)(2)</quote>;</text></clause><clause id="HC9E277DE6A834D1CBFCC804F0934088C"><enum>(iv)</enum><text>in the matter being stricken by paragraph (3), by striking <quote>303(g)(2)(B)</quote> and inserting <quote>303(h)(2)(B)</quote>;</text></clause><clause id="H45EECE36D6354B65887A924BD692888C"><enum>(v)</enum><text>in the matter being stricken by paragraph (5), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>; and</text></clause><clause id="HD4ED6B8F4B224B5A9F209C1340D19992"><enum>(vi)</enum><text>in the matter being stricken by paragraph (6), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>; and</text></clause></subparagraph></paragraph><paragraph id="H88D00955E9AE47EAB5E57424F53A11AB"><enum>(3)</enum><text>section 1263(b) of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref> (136 Stat. 5685) is amended—</text><subparagraph id="H9A11392F563646B1AE8571F0AED7CD28"><enum>(A)</enum><text>by striking <quote>303(g)(2)</quote> and inserting <quote>303(h)(2)</quote>; and</text></subparagraph><subparagraph id="HD204647D70A244DF98C341D5C58E93D0"><enum>(B)</enum><text>by striking <quote>(<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(g)(2)</external-xref>)</quote> and inserting <quote>(<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(h)(2)</external-xref>)</quote>.</text></subparagraph></paragraph></section><section id="H48F2D7C8B097426BB915C228C8131A20"><enum>5.</enum><header>Rulemaking</header><subsection id="H0ADDD1DE49E34AF797834A611DD50598"><enum>(a)</enum><header>Interim final rules</header><text>The Attorney General—</text><paragraph id="H0EEBA749D70F4B88BBD8536D4175B30B"><enum>(1)</enum><text>shall, not later than 6 months after the date of enactment of this Act, issue rules to implement this Act and the amendments made by this Act; and</text></paragraph><paragraph id="HF28FAB2E5BD54E50AD075DF8F35FDDA8"><enum>(2)</enum><text>may issue the rules under paragraph (1) as interim final rules.</text></paragraph></subsection><subsection id="HBDED9F0BC90A4C2AA89A111D28F84825"><enum>(b)</enum><header>Procedure for final rule</header><paragraph id="H44FCC0ACB76E409587D3513A37BE058E"><enum>(1)</enum><header>Effectiveness of interim final rules</header><text>A rule issued by the Attorney General as an interim final rule under subsection (a) shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor, notwithstanding subparagraph (B) of section 553(b) of title 5, United States Code.</text></paragraph><paragraph id="HEB1F2B1EF04A46CA8653E35A3F531CF4"><enum>(2)</enum><header>Opportunity for comment and hearing</header><text>An interim final rule issued under subsection (a) shall give interested persons the opportunity to comment and to request a hearing.</text></paragraph><paragraph id="H43AA7E7E016840978D40B20C6DF5B597"><enum>(3)</enum><header>Final rule</header><text>After the conclusion of such proceedings, the Attorney General shall issue a final rule to implement this Act and the amendments made by this Act in accordance with section 553 of title 5, United States Code.</text></paragraph></subsection></section><section id="HF1EB4D733E484DCF81E901C6A41B1849"><enum>6.</enum><header>Penalties</header><subsection id="H5BD6BFC316C94F6E8847A3CAFD93E913"><enum>(a)</enum><header>In general</header><text>Section 401(b)(1) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/841">21 U.S.C. 841(b)(1)</external-xref>) is amended—</text><paragraph id="H64F6EA8997E5476481CA9CD737C7658E"><enum>(1)</enum><text>in subparagraph (A)(vi), by inserting <quote>or a fentanyl-related substance</quote> after <quote>any analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide</quote>; and</text></paragraph><paragraph id="HDC4EAA5157C04BD8A401CEDF71527E36"><enum>(2)</enum><text>in subparagraph (B)(vi), by inserting <quote>or a fentanyl-related substance</quote> after <quote>any analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide</quote>.</text></paragraph></subsection><subsection id="HCAC16222AFFC465A8182E8A7BF86D84A"><enum>(b)</enum><header>Importation and exportation</header><text>Section 1010(b) of the Controlled Substances Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/960">21 U.S.C. 960(b)</external-xref>) is amended—</text><paragraph id="H2E8E9F67E97F4160B440C5AFA11903F3"><enum>(1)</enum><text>in paragraph (1)(F), by inserting <quote>or a fentanyl-related substance</quote> after <quote>any analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide</quote>; and</text></paragraph><paragraph id="H966AC736F4274EB4B77F4D090CA0088C"><enum>(2)</enum><text>in paragraph (2)(F), by inserting <quote>or a fentanyl-related substance</quote> after <quote>any analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide</quote>.</text></paragraph></subsection></section><section id="H488EA8E0EF95480186EF4BA8E0E6D6B4"><enum>7.</enum><header>Applicability; other matters</header><subsection id="H39B6D8B3C35B42929C6EC7D4D4F5010F"><enum>(a)</enum><header>In general</header><text>Irrespective of the date on which the rules required by section 4 are finalized, the amendments made by this Act apply beginning as of the enactment of this Act.</text></subsection><subsection id="H11D134565D9D43C8834DBCDAF8C48849"><enum>(b)</enum><header>Rule of construction</header><text>Nothing in the amendments made by this Act may be construed as evidence that, in applying sections 401(b)(1) and 1010(b) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/841">21 U.S.C. 841(b)(1)</external-xref> and 960(b)) with respect to conduct occurring before the date of the enactment of this Act, a fentanyl-related substance (as defined by such amendments) is not an analogue of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide.</text></subsection><subsection id="H8A37F36FDDD64E899A211EF830B939DF"><enum>(c)</enum><header>Sense of congress</header><text>The Congress agrees with the interpretation of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>) in United States v. McCray, 346 F. Supp. 3d 363 (2018).</text></subsection></section></legis-body></bill> 

